Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

561. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. (Abstract)

Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Stiripentol is an inhibitor of cytochrome P450 that showed antiepileptic efficacy in severe myoclonic epilepsy in infancy (SMEI) in association with clobazam and valproate in an open study. To confirm these results, 41 children with SMEI were included in a randomised, placebo-controlled, add-on trial.After a baseline period of 1 month, placebo (n=20) or stiripentol (...) . The results also provide good reason to focus studies on a specific epilepsy syndrome-a small sample of patients is sufficient to show the efficacy that might have been missed in a heterogeneous population.

2000 Lancet Controlled trial quality: predicted high

562. Therapeutic drug monitoring in epilepsy treatment

Therapeutic drug monitoring in epilepsy treatment Therapeutic drug monitoring in epilepsy treatment We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Therapeutic drug monitoring in epilepsy treatment Share: Reading time approx. 2 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Findings by SBU (...) Alert This is a translation of version 1, published on May 18, 1998. The latest version of this report is not available in English. Drug monitoring as a means to adapt the dosage of antiepileptic drugs to achieve a particular concentration in blood is well documented. However, there are few studies showing the extent to which drug monitoring contributes toward greater effectiveness in epilepsy treatment as measured by better seizure control. The findings of SBU Alert show that there is currently

2000 Swedish Council on Technology Assessement

563. Gabapentin for drug-resistant partial epilepsy. (Abstract)

Gabapentin for drug-resistant partial epilepsy. The majority of epileptic patients have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic agent, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarise the current evidence regarding a new antiepileptic drug, gabapentin, when used as an add-on treatment for drug-resistant partial epilepsyTo evaluate the efficacy and tolerability of gabapentin (...) when used as an add-on treatment for patients with drug-resistant partial epilepsy.We searched the Cochrane Epilepsy Group trial register, the Cochrane Controlled Trials Register of The Cochrane Library Issue 4, 1998. In addition, we contacted Parke Davis (manufacturers of gabapentin) and experts in the field to seek any ongoing studies or unpublished studies.Randomized placebo controlled double blind add-on trials of gabapentin in patients with drug-resistant partial epilepsy.Two reviewers

2000 Cochrane

564. Zonisamide for drug-resistant partial epilepsy. (Abstract)

Zonisamide for drug-resistant partial epilepsy. The majority of epileptic patients have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic agent, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarise the current evidence regarding a new antiepileptic drug, zonisamide, when used as an add-on treatment for drug-resistant partial epilepsy.To evaluate the efficacy and tolerability of zonisamide (...) when used as an add-on treatment for patients with drug -resistant partial epilepsy.We searched the Cochrane Epilepsy Group trial register, the Cochrane Controlled Trials Register (Cochrane Library Issue 4, 1999). In addition, we contacted Dianippon and Elan Pharma (makers and licensees of zonisamide) and experts in the field to seek any ongoing studies or unpublished studies.Randomized placebo controlled add-on trials of zonisamide in patients with drug-resistant partial epilepsy.Two reviewers

2000 Cochrane

565. Topiramate for drug-resistant partial epilepsy. (Abstract)

Topiramate for drug-resistant partial epilepsy. The majority of epileptic patients have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic agent, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarize the current evidence regarding a new antiepileptic drug, topiramate, when used as an add-on treatment for drug-resistant partial epilepsy.To evaluate the efficacy and tolerability of topiramate (...) when used as an add-on treatment in patients with drug resistant partial epilepsy.(a) The Cochrane Library (1999 Issue 1); (b) The controlled trial register of the Cochrane Epilepsy Group; (c) Johnson and Johnson, makers of topiramate; (d) Experts in the field.Randomized placebo controlled add-on trials of topiramate in patients with drug resistant epilepsy.Two reviewers independently selected trials for inclusion and extracted the relevant data. The following outcomes were assessed: (a) 50

2000 Cochrane

566. Yoga for epilepsy. (Abstract)

Yoga for epilepsy. Stress is considered an important precipitating factor for seizures. Yoga is believed to induce relaxation and stress reduction. The effect of yoga on the EEG and the autonomic nervous system have been reported. Yoga would be an attractive therapeutic option for epilepsy (if proved effective), in view of its nonpharmacological nature, minimal side effects and international acceptance.To assess the efficacy of yoga in the treatment of patients with epilepsy.We searched (...) the Cochrane Epilepsy Group trial register, the Cochrane Controlled Trials Register (The Cochrane Library Issue 4, 1998), MEDLINE for articles published up to the middle of 1998, and also registries of the research council for complimentary medicine were searched. In addition, we searched the references of all the identified studies. Finally, we contacted the members of the Neurological Society of India, several neurophysiology institutions and yoga institutes to seek any ongoing studies or studies

2000 Cochrane

567. Lamotrigine add-on for drug-resistant partial epilepsy. (Abstract)

Lamotrigine add-on for drug-resistant partial epilepsy. Epilepsy is a common neurological disorder, affecting almost 0.5 to 1% of the population. Nearly 30% of patients with epilepsy are refractory to currently available drugs. Lamotrigine is one of the newer antiepileptic drugs and is the topic of this review.To examine the effects of lamotrigine on seizures, side effects, cognition and quality of life, when used as an add-on treatment for patients with drug-resistant partial epilepsy.We (...) searched the Cochrane Epilepsy Group trials register, the Cochrane Controlled Trials Register (Cochrane Library Issue 1, 2000), MEDLINE (January 1966 to December 1999) and reference lists of articles. We also contacted the manufacturers of lamotrigine (Glaxo-Wellcome).Randomized placebo controlled trials, of patients with drug-resistant partial epilepsy of any age, in which an adequate method of concealment of randomization was used. The studies may be double, single or unblinded. For crossover studies

2000 Cochrane

568. Oxcarbazepine add-on for drug-resistant partial epilepsy. (Abstract)

Oxcarbazepine add-on for drug-resistant partial epilepsy. Most people with epilepsy have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic drug, but up to 30 % develop refractory epilepsy, especially those with partial seizures. In this review we summarise the current evidence regarding oxcarbazepine when used as an add-on treatment for drug-resistant partial epilepsy.To evaluate the effects of oxcarbazepine when used as an add-on treatment (...) for drug-resistant partial epilepsy.We searched the Cochrane Epilepsy Group's trials register, the Cochrane Controlled Trials Register (Cochrane Library Issue 1, 2000), MEDLINE (January 1966 to December 1999) and reference lists of articles. We also contacted Novartis (manufacturers of oxcarbazepine) and experts in the field.Randomized, placebo-controlled, double-blind, add-on trials of oxcarbazepine in patients with drug-resistant partial epilepsy.Two reviewers independently assessed trials

2000 Cochrane

569. Carbamazepine versus valproate monotherapy for epilepsy. (Abstract)

Carbamazepine versus valproate monotherapy for epilepsy. Carbamazepine and valproate are drugs of first choice for epilepsy. Despite the lack of hard evidence from individual randomized controlled trials, there is strong clinical belief that valproate is the drug of choice for generalized epilepsies and carbamazepine for partial epilepsies.To overview the best evidence comparing carbamazepine and valproate monotherapyOur search strategy included: (a) MEDLINE 1966-99, (b) The Cochrane Library (...) 1999 issue 4, (c) The trial register of the Cochrane Epilepsy Group (d) the pharmaceutical industry.Randomized controlled trials comparing carbamazepine and valproate monotherapy for epilepsy.This was an individual patient data review. Outcome measures were time to withdrawal of allocated treatment, time to 12 month remission, and time to first seizure post randomization. Data were analysed using the stratified Logrank test with results expressed as hazard ratios (HR) (95% CI), where HR>1 indicates

2000 Cochrane

570. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs Full Text available with Trip Pro

Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs Selai C E, Smith K, Trimble M R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology Adjunctive therapy in epilepsy. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Outpatient epileptic patients. Setting The practice setting was the community. The economic analysis was carried out at the Institute of Psychiatry, London, UK. Dates to which data relate Effectiveness and resource data appear to have been collected during 1998. It was unclear whether

1999 NHS Economic Evaluation Database.

571. The effectiveness of surgery in the management of epilepsy

The effectiveness of surgery in the management of epilepsy The effectiveness of surgery in the management of epilepsy The effectiveness of surgery in the management of epilepsy Chilcott J, Howell S, Kemeny A, Rittey C D, Richards C Authors' objectives To assess the effectiveness of surgery for epilepsy. Searching The authors searched MEDLINE, EMBASE, HealthSTAR and the NHS Centre for Reviews and Dissemination's databases (DARE and NHS EED); the search dates and strategy were not stated (...) . The authors also scanned relevant HTA resources such as websites and booklets, and contacted researchers and practitioners for expert judgement. Study selection Study designs of evaluations included in the review Initial topic searches identified a lack of randomised controlled trials (RCTs) on surgery compared with medical management of intractable epilepsy. The authors therefore included case series and controlled but not randomised case series and one RCT which compared two different forms of surgery

1999 DARE.

572. Cost-benefit of vagus nerve stimulation for refractory epilepsy

Cost-benefit of vagus nerve stimulation for refractory epilepsy Cost-benefit of vagus nerve stimulation for refractory epilepsy Cost-benefit of vagus nerve stimulation for refractory epilepsy Boon P, Vonck K, D'Have M, O'Connor S, Vandekerckhove T, De Reuck J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology Implantation of vagus nerve stimulation (VNS) in the treatment of patients with medically refractory epilepsy who are unsuitable candidates for conventional epilepsy surgery. The Neurocybernetic Prosthesis (NCP) system, which comprises a pulse generator and bipolar helical lead with an integral tether is implanted during a surgical procedure under general anaesthesia. Stimulation is initiated within 2-4 weeks after

1999 NHS Economic Evaluation Database.

573. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. (Abstract)

Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Vigabatrin is a newly licensed drug for use in patients with epilepsy. We investigated whether this drug was comparable to standard first-line monotherapy in efficacy and incidence of adverse events.We enrolled 459 patients with newly diagnosed, previously untreated partial epileptic seizures from 44 European centres (...) . No significant difference was found for time to achieve 6 months of remission from seizures (p=0.058), but the most powerful outcome, time to first seizure after the first 6 weeks from randomisation, showed carbamazepine to be significantly more effective than vigabatrin (p=0.0001).Vigabatrin seems less effective but better tolerated than carbamazepine, which is the first-choice drug for the treatment of partial epilepsies. Vigabatrin cannot therefore be recommended as a first-line drug for monotherapy

1999 Lancet Controlled trial quality: predicted high

574. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK

Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK Shakespeare A, Simeon G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Anti-epileptic drugs used in the treatment of partial or general tonic-clonic seizures. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients, at least 13 years of age, with newly diagnosed cases of epilepsy. Patients had previously

1998 NHS Economic Evaluation Database.

575. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy

An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy Heaney D C, Shorvon S D, Sander J W Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Four drugs used in monotherapy during the first two years of treatment for newly diagnosed patients with epilepsy were compared. These were Carbamazepine (CBZ), Phenytoin (PHT), Valproate (VPA) and Lamotrigine (LTG). Type

1998 NHS Economic Evaluation Database.

576. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy

Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy Markowitz M A, Mauskopf J A, Halpern M T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Anti-epileptic drugs (AEDs) for patients with refractory epilepsy. Type of intervention Treatment. Economic study type Cost-effectiveness analysis Study population Patients over the age of 16 with refractory epilepsy. Setting Hospital. The economic analysis was conducted in Research Triangle Park, North Carolina, USA. Dates to which data relate Data on effectiveness and resource use were collected

1998 NHS Economic Evaluation Database.

577. SPECT brain imaging in epilepsy: a meta-analysis

SPECT brain imaging in epilepsy: a meta-analysis SPECT brain imaging in epilepsy: a meta-analysis SPECT brain imaging in epilepsy: a meta-analysis Devous M D, Thisted R A, Morgan G F, Leroy R F, Rowe C C Authors' objectives To derive the sensitivity and specificity of interictal, postictal or ictal regional cerebral blood flow patterns single-photon enhanced computed tomography (SPECT) brain imaging for the identification of seizure focus in medically refractory patients. Searching Two (...) independent literature searches were performed to identify published articles: EMBASE (via Dialnet) or RadLine (CD-ROM); a manual search of Current Contents. Additional papers were located by examining the reference sections of three comprehensive literature reviews on SPECT imaging in epilepsy (see Other Publications of Related Interest nos.1-3). Conference abstracts, case history reports and narrative reviews were rejected. Study selection Study designs of evaluations included in the review The authors

1998 DARE.

578. Surgery for epilepsy. IPE-98/14 (Public report)

Surgery for epilepsy. IPE-98/14 (Public report) Surgery for epilepsy. IPE-98/14 (Public report) Surgery for epilepsy. IPE-98/14 (Public report) Gonzalez-Enriquez J, Garcia-Comas L, Conde-Olasagasti JL Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Gonzalez-Enriquez J, Garcia-Comas L, Conde-Olasagasti JL. Surgery for epilepsy. IPE-98/14 (...) (Public report) Madrid: Agencia de Evaluacion de Tecnologias Sanitarias (AETS). 1998 Authors' objectives To review the current indications, outcomes and use of epilepsy surgery in Spain. To assess present and future needs for presurgical evaluation and surgical treatment for medically refractory epilepsy. To describe diagnostic and treatment procedures and requirements for service provision. Authors' conclusions At the present time, good results are achieved with several techniques in selected

1998 Health Technology Assessment (HTA) Database.

579. Vagus nerve stimulation in epilepsy

Vagus nerve stimulation in epilepsy Vagus nerve stimulation in epilepsy Vagus nerve stimulation in epilepsy Bryant J, Stein K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bryant J, Stein K. Vagus nerve stimulation in epilepsy. Southampton: Wessex Institute for Health Research and Development (WIHRD) 1998 Authors' objectives The authors (...) examine whether vagus nerve stimulation should be used to treat refractory epilepsy. Authors' conclusions The evidence from the literature suggests that VNS is a safe and effective method of treatment when added to the existing regimen of patients with refractory epilepsy. However, the authors do not feel able to recommend its use. They point out that although the evidence for VNS in epilepsy comes from RCTs of acceptable quality in other respects, the outcome measures are impossible to interpret

1998 Health Technology Assessment (HTA) Database.

580. Lamotrigine as monotherapy for epilepsy in adults

Lamotrigine as monotherapy for epilepsy in adults Lamotrigine as monotherapy for epilepsy in adults Lamotrigine as monotherapy for epilepsy in adults Bryant J, Stein K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bryant J, Stein K. Lamotrigine as monotherapy for epilepsy in adults. Southampton: Wessex Institute for Health Research (...) and Development (WIHRD) 1998 Authors' objectives The author investigates whether lamotrigine should be used as monotherapy for treating epilepsy in adults, in place of the established antiepileptic drugs, and whether it should be used as add-on therapy. Authors' conclusions LTG may be a good option for patients with poorly controlled epilepsy due to treatment-limiting side effects, and those with a history of drug intolerance but adequate seizure control, but skin reactions are common and may be serious

1998 Health Technology Assessment (HTA) Database.